Cholesterol derivatives based charged liposomes for doxorubicin delivery: Preparation, in vitro and in vivo characterization

Theranostics

Volumn 2, Issue 11, 2012, Pages 1092-1103

  Nie, Yu ^a   Ji, Li ^a   Ding, Hong ^b   Xie, Li ^a   Li, Li ^a   He, Bin ^a   Wu, Yao ^a   Gu, Zhongwei ^a  

^a SICHUAN UNIVERSITY   (China)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Charged; Cholesterol derivative; Drug delivery; Image; Liposome; PEGylation

Indexed keywords

CHOLESTEROL DERIVATIVE; DOXORUBICIN; LIPOSOME; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER MORTALITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; ENCAPSULATION; FLOW CYTOMETRY; HEMOLYSIS; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA CELL; MOUSE; NONHUMAN;

CHARGED; CHOLESTEROL DERIVATIVE; DRUG DELIVERY.; IMAGE; LIPOSOME; PEGYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL AGING; CELL DEATH; CELL LINE, TUMOR; CHOLESTEROL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; HEMOLYSIS; HUMANS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; STATIC ELECTRICITY;

EID: 84870484306     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4949     Document Type: Article

References (48)

1. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. Journal of Controlled Release 2004; 100: 135-144.
2. Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine 2008; 3: 761-776.
3. Torchilin VP, Levchenko TS, Rammohan R et al. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci U S A 2003; 100: 1972-1977.
4. Buyens K, De Smedt SC, Braeckmans K et al. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J Control Release 2012; 158: 362-370.
5. Park K. Comparative study on liposome targeting to tumor endothelium. J Control Release 2012; 158: 181.
6. Peng A, Kosloski M, Nakamura G et al. PEGylation of a Factor VIII-Phosphatidylinositol Complex: Pharmacokinetics and Immunogenicity in Hemophilia A Mice. The AAPS Journal 2012; 14: 35-42.
7. Addeo R, Faiola V, Guarrasi R et al. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age. Cancer Chemother Pharmacol 2008; 62: 285-292.
8. Kuang Y, Liu J, Liu Z, Zhuo R. Cholesterol-based anionic long-circulating cisplatin liposomes with reduced renal toxicity. Biomaterials 2012; 33: 1596-1606.
9. Abu Lila AS, Kizuki S, Doi Y et al. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release 2009; 137: 8-14.
10. Dragicevic-Curic N, Grafe S, Gitter B et al. Surface charged temoporfin-loaded flexible vesicles: in vitro skin penetration studies and stability. Int J Pharm 2010; 384: 100-108.
11. Wu J, Lee A, Lu Y, Lee RJ. Vascular targeting of doxorubicin using cationic liposomes. Int J Pharm 2007; 337: 329-335.
12. Levchenko TS, Rammohan R, Lukyanov AN et al. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm 2002; 240: 95-102.
13. Luk BT, Fang RH, Zhang L. Lipid- and Polymer-Based Nanostructures for Cancer Theranostics. Theranostics 2012.
14. Soenen SJ, Brisson AR, De Cuyper M. Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model. Biomaterials 2009; 30: 3691-3701.
15. Dan N. Effect of liposome charge and PEG polymer layer thickness on cell-liposome electrostatic interactions. Biochim Biophys Acta 2002; 1564: 343-348.
16. Moghimi SM, Patel HM. Modulation of murine liver macrophage clearance of liposomes by diethylstilbestrol. The effect of vesicle surface charge and a role for the complement receptor Mac-1 (CD11b/CD18) of newly recruited macrophages in liposome recognition. J Control Release 2002; 78: 55-65.
17. Miller CR, Bondurant B, McLean SD et al. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 1998; 37: 12875-12883.
18. Lee KD, Nir S, Papahadjopoulos D. Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry 1993; 32: 889-899.
19. Allen TM, Austin GA, Chonn A et al. Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim Biophys Acta 1991; 1061: 56-64.
20. Lee KD, Hong K, Papahadjopoulos D. Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim Biophys Acta 1992; 1103: 185-197.
21. Wu F, Bhansali SG, Tamhane M et al. Noninvasive real-time fluorescence imaging of the lymphatic uptake of BSA-IRDye 680 conjugate administered subcutaneously in mice. J Pharm Sci 2012; 101: 1744-1754.
22. Ding H, Yong K-T, Roy I et al. Gold Nanorods Coated with Multilayer Polyelectrolyte as Contrast Agents for Multimodal Imaging. The Journal of Physical Chemistry C 2007; 111: 12552-12557.
23. Ding H, Wu F. Images Guided Biodistribution and Pharmacokinetic Studies of Theranostics. Theranostics 2012; doi:10.7150/thno.4652.
24. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev 2012.
25. Zhou Y, Chakraborty S, Liu S. Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics 2011; 1: 58-82.
26. Heneweer C, Gendy SE, Penate-Medina O. Liposomes and inorganic nanoparticles for drug delivery and cancer imaging. Ther Deliv 2012; 3: 645-656.
27. Li L, Nie Y, Zhu R et al. Preparation and gene delivery of alkaline amino acids-based cationic liposomes. Arch Pharm Res 2008; 31: 924-931.
28. Xu H, Deng Y, Chen D et al. Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives. J Control Release 2008; 130: 238-245.
29. Bolotin EM, Cohen R, Bar LK et al. Ammonium Sulfate Gradients for Efficient and Stable Remote Loading of Amphipathic Weak Bases into Liposomes and Ligandoliposomes. Journal of Liposome Research 1994; 4: 455-479.
30. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993; 1151: 201-215.
31. Duan Y, Nie Y, Gong T et al. Evaluation of blood compatibility of MeO-PEG-poly (D, L-lactic-co-glycolic acid)-PEG-OMe triblock copolymer. Journal of Applied Polymer Science 2006; 100: 1019-1023.
32. Dadashzadeh S, Mirahmadi N, Babaei MH, Vali AM. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge. J Control Release 2010; 148: 177-186.
33. Cui J, Li C, Guo W et al. Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy? Journal of Controlled Release 2007; 118: 204-215.
34. Gardikis K, Tsimplouli C, Dimas K et al. New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers. Int J Pharm 2010; 402: 231-237.
35. Liu J, Jiang X, Ashley C, Brinker CJ. Electrostatically mediated liposome fusion and lipid exchange with a nanoparticle-supported bilayer for control of surface charge, drug containment, and delivery. J Am Chem Soc 2009; 131: 7567-7569.
36. Xiao K, Li Y, Luo J et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 2011; 32: 3435-3446.
37. Domański DM, Klajnert B, Bryszewska M. Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry 2004; 63: 189-191.
38. Wang W, Xiong W, Zhu Y et al. Protective effect of PEGylation against poly(amidoamine) dendrimer-induced hemolysis of human red blood cells. J Biomed Mater Res B Appl Biomater 2010; 93: 59-64.
39. Ding H, Yong K-T, Roy I et al. Bioconjugated PLGA-4-arm-PEG branched polymeric nanoparticles as novel tumor targeting carriers. Nanotechnology 2011; 22: 165101.
40. Jung SH, Jung SH, Seong H et al. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Int J Pharm 2009; 382: 254-261.
41. He C, Hu Y, Yin L et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010; 31: 3657-3666.
42. Roser M, Fischer D, Kissel T. Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 1998; 46: 255-263.
43. Lundqvist M, Stigler J, Elia G et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A 2008; 105: 14265-14270.
44. Hafez IM, Cullis PR. Cholesteryl hemisuccinate exhibits pH sensitive polymorphic phase behavior. Biochimica et Biophysica Acta (BBA) -Biomembranes 2000; 1463: 107-114.
45. Reddy LH, Murthy RS. Pharmacokinetics and biodistribution studies of Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2004; 148: 161-166.
46. Osman A-MM, Nemnem MM, Abou-Bakr AA et al. Effect of methimazole treatment on doxorubicin-induced cardiotoxicity in mice. Food and Chemical Toxicology 2009; 47: 2425-2430.
47. Pereverzeva E, Treschalin I, Bodyagin D et al. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: Focus on cardio- and testicular toxicity. Int J Pharm 2007; 337: 346-356.
48. Pereverzeva E, Treschalin I, Bodyagin D et al. Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. Toxicology Letters 2008; 178: 9-19.